Inotiv Inc., a contract research organization serving biopharma and medical device companies, has outlined its latest strategic initiatives and operational updates in a recent investor presentation. The company highlighted its vertically integrated business model, which includes Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments, addressing an estimated $25 billion total addressable market. Recent efforts focus on optimizing sites for cost savings, improved logistics, and enhanced client experiences. Inotiv has strengthened its compliance framework by appointing a Chief Compliance Officer, establishing a Compliance Committee, and implementing a nationwide compliance plan. The company is also modernizing data management for research animals and unifying procedures across U.S. operations. Commercial strategies include the expansion of dedicated sales teams, a consultative sales approach, and the promotion of multi-site capabilities for client studies. Inotiv's ongoing strategic evolution emphasizes integration and optimization of acquired entities and continued growth through both organic investments and opportunistic mergers and acquisitions. You can access the full presentation through the link below.